What is the generic name of Jemperli?

The generic name is dostarlimab-gxly, a PD-1 blocking antibody.

Who manufactures Jemperli?

Jemperli is manufactured by GlaxoSmithKline.

What type of drug is Jemperli?

It is an immune checkpoint inhibitor that blocks PD-1, helping the immune system recognize and attack cancer cells.

Is Jemperli FDA-approved?

Yes. Jemperli is FDA-approved for primary advanced or recurrent endometrial cancer, dMMR recurrent or advanced endometrial cancer, and dMMR solid tumors. In October 2026 it also received accelerated approval for Stage II/III dMMR or MSI-H locally advanced rectal cancer.

What is Jemperli used for?

Jemperli is used to treat endometrial cancer, other dMMR/MSI-H solid tumors and, since October 2026, dMMR/MSI-H locally advanced rectal cancer, either alone or combined with chemotherapy depending on the indication.

What is the dosage form of Jemperli?

Jemperli is supplied as an injectable solution for intravenous infusion, 500 mg/10 mL per vial.

What is the typical dosing schedule?

Dosing varies by indication: typically 500 mg IV every 3 weeks for the first several doses, followed by 1000 mg IV every 6 weeks as maintenance. For locally advanced rectal cancer, it is 500 mg IV every 3 weeks for up to 9 cycles.

What are the common side effects of Jemperli?

Common side effects include anemia, diarrhea, nausea, vomiting, and joint pain. Serious risks include immune-mediated reactions affecting the lungs, liver, colon, and endocrine glands.

How can I import Jemperli to India?

Jemperli can be imported through a regulated Named Patient Program with a valid prescription, supported by NPP's documentation and cold-chain logistics process.

Why should I use a reliable supplier for Jemperli?

A verified supplier ensures product authenticity, proper cold-chain handling, and regulatory compliance, which is critical for this immunotherapy.

What is the Jemperli (dostarlimab) price in India?

The price depends on the dose and the number of vials. Each vial is 500 mg/10 mL, so a 500 mg dose uses one vial and a 1,000 mg dose uses two. Import and cold-chain logistics are added to the medicine cost. Share your prescription with NPP to get a clear, itemised quotation.

How many vials of Jemperli are needed for one dose?

Jemperli is supplied only as a 500 mg/10 mL vial. The 500 mg dose given every 3 weeks at the start of treatment uses one vial; the 1,000 mg dose given every 6 weeks later uses two vials. Your oncologist decides the schedule.

Can I buy Jemperli without a prescription?

No. Jemperli is a prescription-only cancer immunotherapy. Import through a Named Patient Program needs a valid prescription from the treating oncologist and supporting clinical documents.

Can patients from SAARC or Gulf countries access Jemperli through NPP?

Yes, NPP supports patients from SAARC and Gulf countries through the same regulated import pathway, subject to local regulatory requirements.

How should Jemperli be stored?

Store refrigerated at 2°C to 8°C. Do not freeze.

Call Us for Support

+91 9654860915

Google Reviews

4.8

Cities We Serve How to Order Online Order

About Us Named Patient Program

Cities We Serve Contact Us

Sourced directly from the authorized manufacturer network to ensure authenticity and quality.

Ready to proceed? Order Jemperli on our secure patient portal to submit your prescription, upload documents and track your approval status.

Jemperli

Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.

Medicine Name: Jemperli

Generic Name (API): Dostarlimab-gxly

Dosage Form & Strength: 500 mg/10 mL

Route: Intravenous

Drug Class: PD-1 (programmed death receptor-1) blocking antibody, immune checkpoint inhibitor

Manufacturer / Innovator:

GlaxoSmithKline

Regulatory Approval:

FDA (US)
EMA (Europe)
HC (Canada)

Prescribing Information Resources

Family enjoying life with Named Patient Program access

Your Trustworthy Partner For Named Patient Program

Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.

GDP Compliant View Certificate

Licensed Wholesale distributor View Certificate

Understanding Jemperli (Dostarlimab-gxly) and Its Medical Uses

Jemperli (dostarlimab-gxly) is a PD-1 blocking antibody that helps the immune system recognize and attack cancer cells by blocking a checkpoint protein that tumors use to evade immune detection.

Approved Indications

Jemperli, combined with carboplatin and paclitaxel followed by Jemperli monotherapy, is FDA-approved for adult patients with primary advanced or recurrent endometrial cancer. As a single agent, it is also approved for mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed after platinum-based treatment, and for dMMR solid tumors that have progressed after prior treatment with no satisfactory alternative options. In October 2026, the FDA also granted accelerated approval for Stage II/III dMMR or MSI-H locally advanced rectal cancer; the trial results are explained in our Jemperli rectal cancer approval update.

How It Works

Dostarlimab binds to PD-1 receptors on T-cells, blocking their interaction with PD-L1/PD-L2 on tumor cells, which restores the immune system's ability to identify and destroy cancer cells.

Dosing

For primary advanced or recurrent endometrial cancer, the dose is 500 mg IV every 3 weeks for 6 doses as part of chemotherapy combination, then 1000 mg IV every 6 weeks as monotherapy for up to 3 years. For dMMR indications, dosing is 500 mg IV every 3 weeks for 4 doses, then 1000 mg IV every 6 weeks, as determined by the treating oncologist. For dMMR or MSI-H locally advanced rectal cancer (approved October 2026), the dose is 500 mg IV every 3 weeks for up to 9 cycles.

Warnings and Precautions for Jemperli

As a PD-1 immune checkpoint inhibitor, Jemperli can cause immune-mediated adverse reactions affecting multiple organ systems, which may be severe or fatal and can occur even after treatment discontinuation.

Immune-Mediated Pneumonitis

Monitor for new or worsening respiratory symptoms; manage with corticosteroids and treatment interruption as needed.

Immune-Mediated Colitis

Monitor for diarrhea or signs of colitis.

Immune-Mediated Hepatitis and Endocrinopathies

Monitor liver function tests and thyroid/other hormone levels periodically during treatment.

Immune-Mediated Nephritis and Skin Reactions

Monitor kidney function and for skin changes throughout treatment.

Infusion-Related Reactions

Monitor during and after infusion for hypersensitivity reactions.

Embryo-Fetal Toxicity

Jemperli can cause fetal harm. Effective contraception is required during treatment and for 4 months after the final dose; breastfeeding is not recommended during this period.

Immune-mediated reactions can occur even after treatment ends — report new symptoms promptly, even after finishing therapy.
Regular monitoring of organ function is required throughout treatment.
Follow the combination-therapy monitoring schedule set by the treating oncologist.

How to Access Jemperli in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation and Availability of Jemperli

Jemperli (dostarlimab-gxly) is manufactured by GlaxoSmithKline and is approved for multiple endometrial cancer indications as well as dMMR solid tumors.

Jemperli (Dostarlimab) Price in India: What Decides the Cost

Through a Named Patient Program, the cost of Jemperli is quoted for each order, because it depends on the treatment plan your oncologist has written. These are the main things that decide the final dostarlimab price in India:

Number of vials: Jemperli comes in one strength only, a 500 mg/10 mL single-dose vial. A 500 mg dose needs one vial; a 1,000 mg dose needs two vials.
Stage of treatment: treatment usually starts with 500 mg every 3 weeks (6 cycles with chemotherapy, or 4 cycles when Jemperli is given alone). After that the dose becomes 1,000 mg every 6 weeks, so the number of vials per cycle changes.
Cold-chain import: Jemperli must stay at 2°C to 8°C from the supplier to your hospital, and every shipment needs customs and import documents.
Quantity per order: ordering for one cycle or several cycles changes the logistics cost per vial.

To get the current price, share the prescription with our team. You will receive an itemised quotation that shows the medicine cost, logistics and delivery timeline. Be careful with any seller that offers Jemperli without a prescription: it is a prescription-only immunotherapy, and a genuine supply must come with full import and cold-chain records.

Documentation Required

Import of Jemperli through a Named Patient Program requires a valid prescription from the treating oncologist, confirmation of diagnosis and biomarker (dMMR/MSI-H) status where relevant, and supporting clinical documentation as required by Indian regulatory authorities.

Sourcing

NPP sources Jemperli directly from GlaxoSmithKline's authorized supply chain to ensure product authenticity and regulatory compliance.

Sourcing and Delivery of Jemperli

Jemperli is sourced through verified, GDP-compliant, cold-chain channels from GlaxoSmithKline's authorized supply chain to ensure authenticity and quality.

Storage Requirements

Jemperli should be stored refrigerated at 2°C to 8°C. Do not freeze.

Delivery Process

Once sourced, Jemperli is packed and transported under continuous cold-chain conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.

Availability of Jemperli Across Major Cities in India

Patients across India can access Jemperli through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.